AAV9-Follistatin

The compound "AAV9-Follistatin" involves using an adeno-associated virus vector (AAV9) to deliver the follistatin gene into the body. The primary goal of this therapy is to enhance muscle mass and function, especially in the context of age-related muscle loss.

Molecular Mechanism:

1. Gene Delivery: AAV9 serves as a vector to introduce the follistatin gene into target cells. AAV9 is chosen for its efficiency in targeting muscle cells and minimal immune response.

2. Follistatin Expression: Once inside the muscle cells, the follistatin gene is transcribed and translated into the follistatin protein.

3. Myostatin Inhibition: Follistatin acts as a potent inhibitor of myostatin, a protein that restricts muscle growth. By binding to myostatin, follistatin prevents it from interacting with its receptor, allowing for increased muscle protein synthesis and growth.

4. Muscle Growth Promoter: The overall result is enhanced muscle growth and improved muscle function due to the reduction in myostatin activity.

Physiological Level:

• The combined therapy mentioned in the trial (NCT07443826) also includes a VEGF plasmid. VEGF (Vascular Endothelial Growth Factor) enhances blood supply and angiogenesis, potentially improving nutrient delivery and further supporting muscle health.

The clinical trial status is currently in Phase 1 and Phase 2, which suggests ongoing evaluation of safety, dosage, and initial efficacy.

Disclaimer: This information is for educational purposes only and not for medical advice. Always consult healthcare professionals for medical concerns.

Clinical Applications of AAV9-Follistatin

AAV9-Follistatin is currently under investigation for its potential use in addressing age-related muscle loss. The therapy is part of a clinical trial named CALM-AF-AI, which combines AAV9-Follistatin with a VEGF plasmid gene therapy to promote muscle growth and vascular health. This trial targets counteracting muscle atrophy linked to aging by enhancing muscle mass and strength while potentially improving blood supply to the muscles.

As of now, there are no published results from this trial as it is still in the recruiting phase. Without further data or completed studies, detailed conclusions on the efficacy and safety of AAV9-Follistatin for age-related muscle loss remain pending. This indicates an evolving field with promising potential, but concrete clinical applications are yet to be established based on trial outcomes.

Disclaimer: This information is educational and should not substitute professional medical advice. Consult a healthcare provider for personalized guidance.

Currently, there is limited evidence regarding the safety profile of AAV9-Follistatin due to the absence of published studies or safety data retrieved from PubMed. The ongoing clinical trial (NCT07443826) aims to investigate this therapy's effects but is still in the recruiting phase (Phase 1/2). As such, comprehensive safety information, including known side effects, contraindications, drug interactions, and specific populations that should avoid this therapy, is not yet available.

The absence of detailed data means that any conclusions about the safety of AAV9-Follistatin are speculative at this point. Further research outcomes from the ongoing trial will be necessary to develop a more complete understanding of the safety profile.

Disclaimer: This is general information and should not be considered medical advice. Please consult healthcare professionals for personal medical concerns.

Currently, there appear to be no published research papers on "AAV9-Follistatin" in the PubMed database. However, there is an ongoing clinical trial related to this therapy.

The clinical trial, identified as NCT07443826, is titled "CALM-AF-AI: Counteracting Age-related Loss of Muscle With AAV-Follistatin Combined With Angiogenesis-Inducing VEGF Plasmid Gene Therapy." This trial is in the recruitment phase and spans Phase 1 and Phase 2. It aims to explore the effects of combining AAV9-Follistatin with a VEGF plasmid gene therapy to address muscle loss associated with aging. Currently, specific outcomes or data from this study are not available, as it is still in progress.

Given the lack of published literature, any conclusions about the efficacy or safety of AAV9-Follistatin are pending the results of ongoing studies.

Disclaimer: This content is for informational purposes only and should not be used as medical advice. Always consult healthcare professionals for medical concerns.

The current understanding of dosing and administration protocols for AAV9-Follistatin is limited, as no specific guidelines or completed clinical trials appear in the PubMed database. However, ongoing research, such as the clinical trial registered with NCT ID: NCT07443826, may provide insights into potential protocols in the future.

This trial, titled "CALM-AF-AI: Counteracting Age-related Loss of Muscle With AAV-Follistatin Combined With Angiogenesis-Inducing VEGF Plasmid Gene Therapy," is currently in the recruiting stage and has not yet reached completion. It is a Phase 1/Phase 2 trial aimed at investigating the effects and safety of this combined gene therapy approach.

As no explicit dosing information is available yet, practitioners and patients should rely on the results of this and other trials once they are published. It's essential to follow official guidance from healthcare professionals and regulatory authorities.

Disclaimer: This information is not intended as personalized medical advice. Always consult a qualified healthcare provider for recommendations tailored to your individual circumstances.

The outcomes for the AAV9-Follistatin therapy based on current literature are not well-documented, as comprehensive data from studies or trials have not yet been published. The clinical trial NCT07443826, titled "CALM-AF-AI," is currently in the recruiting phase, combining AAV-Follistatin with VEGF plasmid gene therapy. This trial is likely focused on assessing the potential benefits for age-related muscle loss by measuring changes such as muscle strength or size, biomarkers of muscle regeneration, or functional improvements.

However, without published results from this trial or any relevant studies available in PubMed, the strength of evidence regarding the efficacy or safety of AAV9-Follistatin is currently very limited. More conclusive outcomes will depend on future data from ongoing or forthcoming research.

Disclaimer: This summary is intended for informational purposes only and should not be taken as medical advice. Always consult with a healthcare professional for medical concerns.